CSII News and Press, Cardiovascular Systems Inc. From 05/04/22

Conference Call Scheduled for Today, May 4, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $56.2 million decreased 4.9% sequentially compared to second quarter this year and decreased 11.1% compared to third quarter last year Fiscal year 22 revenue guidance narrowe...

Cardiovascular Systems (NASDAQ:CSII) is scheduled to announce Q3 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is -$0.33 (vs. -$0.15 in prior year) and the consensus Revenue Estimate is $57.38M (-9.3% Y/Y). Over the last 3 months, EPS estimat...

ABC,AMRN,AMRX,ASC,ATI,AVA,AVNS,BDC,BIP,BLX,BRKR,BRY,BWA,CDW,CFMS,CGAU,CLDT,CLH,CLVS,CMLS,CRL,CRTO,CSII,CVS,DCPH,DIN,DOC,OTCPK:EADSF,EAT,EDIT,EMR,OTCPK:ENLAY,EXPI,EYPT,FDP,FMS,OTCPK:FSNUF,FTS,FUN,GEL,GNRC,GOLD,GTHX,HZNP,IDXX,IMKTA,INSW,IONS,ISEE,JCI,JHG,OTCPK:LBLCF,LITE,LL,LNG,MAR,MCRB,MFA,MIR...

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) plans to announce its operating results for the quarter ended March 31, 2022 before the market opens on Wednesday, May 4, 2022, and will host a conference call at 8:00 a.m. CT (9:00 a.m. ET) that day to discuss those results....

Shares of Cardiovascular Systems Inc. (NASDAQ:CSII) traded at a new 52-week high today of $55.11. Approximately 17.5 million shares have changed hands today, as compared to an average 30-day volume of 282,000 shares. In the past 52 weeks, shares of Cardiovascular Systems Inc. have traded...

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host inve...

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the first in-human experience with Propel!...

Cardiovascular Systems (NASDAQ:CSII) said enrollment has begun in a first in-human trial of peripheral everolimus drug-coated balloon (DCB) being developed by Chansu Vascular Technologies. The company said DCBs are a widely accepted percutaneous interventional treatment option for f...

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in a first in-human tr...

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer....